Thalassemia major. Beta thalassemia major
Conditions
Interventions
Treatment by Deferiprone with a dose of 50-100 mg/kg daily associated with treatment by Deferoxamine with a dose of 50-30 mg/kg for 3 nights weekly.
Treatment - Drugs
Treatment by Deferiprone with a dose of 50-100 mg/kg daily associated with treatment by Deferoxamine with a dose of 50-30 mg/kg for 3 nights weekly
Sponsors
Golestan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients were treated with iron chelators Subcutaneous Deferoxamine with a doseof 30-50 mg/kg for 5 nights a week for 3 years before starting the study. Exclusion criteria: gastrointestinal complications; failure to cooperate in the control tests (ALT, CBC); becoming tired of the traffic for controlling consumption of deferiprone
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left Venticular Ejection Fraction. Timepoint: It is messured for 3 years at the end of each year. Method of measurement: Echocardiography.;Srum ferritin. Timepoint: It is messured for 3 years at the end of each year. Method of measurement: Determining the level of serum ferritin by related test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNarges beigom Mirbehbahani
Hematology & Oncology Research Center, Golestan University of Medical Sciences
Outcome results
None listed